Kiora Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Will Present Additional Data From Its ABACUS-1 Trial of KIO-301 in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Kiora Pharmicals 宣布将在 ARVO 2024 年年会上公布其针对色素性视网膜炎的 KIO-301 的 ABACUS-1 试验的更多数据后,该公司股价走高